Roman K. Thomas

Roman K. Thomas, T. Zander, K. Ernestus, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

C. Rudin, J. Minna, Roman K. Thomas, 2019, Nature Reviews Cancer.

Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines.

V. Diehl, Roman K. Thomas, M. Teitell, 2005, Journal of molecular biology.

Unhappy neighbourhood: spatial genome organisation and lymphomagenesis in B cells

V. Diehl, Roman K. Thomas, 2003, The Lancet.

Chromothripsis followed by circular recombination drives oncogene amplification in human cancer

J. Korbel, A. Stütz, Roman K. Thomas, 2021, Nature Genetics.

Efficient Activation of Autologous Tumor-specific T Cells: A Simple Coculture Technique of Autologous Dendritic Cells Compared to Established Cell Fusion Strategies in Primary Human Colorectal Carcinoma

Roman K. Thomas, M. Beyer, J. Schultze, 2007, Journal of immunotherapy.

PD-L1 expression and genotype in non-small cell lung cancer (NSCLC).

H. Groen, M. Hellmich, Roman K. Thomas, 2014 .

Repeated Clonal Relapses in Classical Hodgkin's Lymphoma and the Occurrence of a Clonally Unrelated Diffuse Large B Cell Non-Hodgkin Lymphoma in the Same Patient

V. Diehl, Roman K. Thomas, H. Tesch, 2004, Leukemia & lymphoma.

Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities

G. Giaccone, G. Ott, M. Kriegsmann, 2022, Cell Death & Disease.

DSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity

Roman K. Thomas, E. Felip, I. Melero, 2022, The Journal of experimental medicine.

Functional synapses between small cell lung cancer and glutamatergic neurons

G. Reifenberger, K. Conzelmann, R. Rad, 2023, bioRxiv.

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

William Pao, Zhongming Zhao, Ronglai Shen, 2014, Nature Medicine.

Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.

M. Meyerson, P. Jänne, H. Ji, 2007, Cancer cell.

Standardized high-throughput evaluation of cell-based compound screens

Roman K. Thomas, Peter Frommolt, Roman K. Thomas, 2008, BMC Bioinformatics.

RETRACTED: Cytohesins Are Cytoplasmic ErbB Receptor Activators

Roman K. Thomas, M. Famulok, P. Verveer, 2010, Cell.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

I. Weissman, M. van de Rijn, C. Rudin, 2016, The Journal of clinical investigation.

Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis

Yingyong Hou, H. Ji, Roman K. Thomas, 2021, bioRxiv.

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

C. Rudin, J. Minna, Roman K. Thomas, 2019, Nature Reviews Cancer.

MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

Kristofer C. Berrett, Roman K. Thomas, A. Gazdar, 2017, Cancer cell.

CD74-NRG1 fusions in lung adenocarcinoma.

I. Petersen, S. Haas, M. Vingron, 2014, Cancer discovery.

Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death

Roman K. Thomas, O. Schilling, R. Schüle, 2020, Cancer Cell International.

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

Laura Tolosi, Michael Peyton, Thomas Zander, 2009, The Journal of clinical investigation.

Somatic Genome Alterations in Human Lung Cancers

M. Meyerson, Roman K. Thomas, P. Hammerman, 2014 .

Fibroblast growth factor receptors as therapeutic targets in neuroblastoma

Roman K. Thomas, M. Peifer, F. Ikram, 2014 .

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

Roman K. Thomas, W. Pao, C. Liang, 2011, Cancer research.

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

Li Ding, William Pao, Elaine R Mardis, 2008, Cancer research.

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

A. Trumpp, A. Bradley, R. Rad, 2015, Cell.

Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer

Jing Wang, Roman K. Thomas, I. Wistuba, 2021, Nature Communications.

Genomic Ampli fi cation of CD 274 ( PD-L 1 ) in Small-Cell Lung Cancer

I. Petersen, J. Yokota, C. Harris, 2017 .

Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer

I. Petersen, J. Yokota, C. Harris, 2016, Clinical Cancer Research.

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.

Levi A Garraway, Lynda Chin, Kwok-Kin Wong, 2007, Cancer research.

Amplification of chromosomal segment 4q12 in non-small cell lung cancer

M. Meyerson, M. Rubin, R. Beroukhim, 2009, Cancer biology & therapy.

A tuft cell-like signature is highly prevalent in thymic squamous cell carcinoma and delineates new molecular subsets among the major lung cancer histotypes.

G. Ott, A. Marx, M. Kriegsmann, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

Herbert Waldmann, Takashi Ninomiya, Martin Peifer, 2012, Proceedings of the National Academy of Sciences.

Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204‐PDGFRB fusion in a patient with recurrent T‐ALL and an associated myeloproliferative neoplasm

Annette S. Kim, N. Socci, A. Viale, 2012, Genes, chromosomes & cancer.

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data

I. Petersen, S. Haas, M. Vingron, 2015, Genome Biology.

Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities

Elisabeth Brambilla, Roman K. Thomas, E. Brambilla, 2012, Clinical Cancer Research.

Genomic Approaches to Lung Cancer

M. Meyerson, B. Weir, Roman K. Thomas, 2006, Clinical Cancer Research.

Therapeutics , Targets , and Chemical Biology Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors

E. Stanchina, Roman K. Thomas, W. Pao, 2011 .

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Derek Y. Chiang, Matthew Meyerson, William G. Richards, 2008, Clinical Cancer Research.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

G. Giaccone, M. Krasnow, C. Rudin, 2022 .

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

I. Petersen, D. Hayes, M. Wilkerson, 2018, Nature Communications.

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer

Roman K. Thomas, V. Walter, Filippo Beleggia, 2017, Scientific Reports.

Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer

Roman K. Thomas, M. Peifer, J. Wolf, 2017, Clinical Cancer Research.

Malignant Melanoma Modeling Genomic Diversity and Tumor Dependency in Updated

T. Golub, G. Getz, M. Meyerson, 2008 .

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

Zhongming Zhao, N. Socci, A. Viale, 2010, Nucleic acids research.

Cytohesins Are Cytoplasmic ErbB Receptor Activators

Roman K. Thomas, M. Famulok, P. Verveer, 2010 .

Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes

Roman K. Thomas, M. Sos, Filippo Beleggia, 2020, Nature Communications.

In vitro model for resistance in oncogene-dependent tumors at the limit of radiological detectability

Roman K. Thomas, M. Peifer, M. Sos, 2019, bioRxiv.

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

N. Socci, A. Viale, M. Ladanyi, 2011, Science Translational Medicine.

A flexible rank-based framework for detecting copy number aberrations from array data

Thomas LaFramboise, Wendy Winckler, Roman K. Thomas, 2009, Bioinform..

Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor Pathway

Roman K. Thomas, T. Zander, J. Wolf, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Mehmet Toner, Martin Peifer, Mari Mino-Kenudson, 2018, Cancer discovery.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

M. Meyerson, I. Petersen, R. Onofrio, 2011, Cancer discovery.

in squamous cell lung cancer

M. Meyerson, I. Petersen, R. Onofrio, 2011 .

Mutations in the DDR 2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer

M. Meyerson, I. Petersen, R. Onofrio, 2011 .

MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

C. Schmitt, Roman K. Thomas, G. Hartmann, 2021, Nature Communications.

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Roman K. Thomas, W. Pao, R. Küppers, 2012, Clinical Cancer Research.

Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.

Roman K. Thomas, J. Heuckmann, D. Rauh, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Therapy : Preclinical See commentary by Crystal and Shaw , p . 4479 Differential Protein Stability and ALK Inhibitor Sensitivity of EML 4-ALK Fusion Variants

Roman K. Thomas, W. Pao, M. Peifer, 2012 .

Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.

Roman K. Thomas, M. Sos, W. V. van Otterlo, 2010, Journal of medicinal chemistry.

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

Martin Peifer, Daniel Rauh, Lars Ruddigkeit, 2010, Cancer research.

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.

M. Meyerson, A. Lowell, D. Tenen, 2008, Cancer research.

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

M. Meyerson, A. Lowell, H. Ji, 2006, Cancer research.

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

M. Meyerson, A. Protopopov, Xiaojun Zhao, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.

Roman K. Thomas, G. Christofori, M. Peifer, 2013, The Journal of clinical investigation.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Roman K. Thomas, F. Cappuzzo, E. Smit, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids

Martin Vingron, Thomas Zander, Viktor Achter, 2014, Nature Communications.

Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens

Roman K. Thomas, T. Zander, K. Ernestus, 2011, PloS one.

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

M. Meyerson, C. Mermel, B. Weir, 2009, Cancer research.

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity

M. Meyerson, D. Hayes, Roman K. Thomas, 2009, Oncogene.

Allelic losses on chromosome 6q25 in Hodgkin and Reed Sternberg cells.

V. Diehl, Roman K. Thomas, P. Starostik, 2003, Cancer research.

The major subtypes of human B‐cell lymphomas lack mutations in BCL‐2 family member BAD

Roman K. Thomas, R. Küppers, J. Wolf, 2006, International journal of cancer.

Hodgkin-Lymphom (Morbus Hodgkin)

V. Diehl, Roman K. Thomas, M. Pfreundschuh, 2006 .

Part II: Hodgkin's lymphoma--diagnosis and treatment.

V. Diehl, Roman K. Thomas, D. Ré, 2004, The Lancet Oncology.

Blood-Based Gene Expression Signatures in Non–Small Cell Lung Cancer

Thomas Zander, Andrea Hofmann, Joachim L Schultze, 2011, Clinical Cancer Research.

Era of comprehensive cancer genome analyses.

Roman K. Thomas, Y. Yatabe, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensivegenomiccharacterization of squamous cell lung cancers

Joshua M. Stuart, Derek Y. Chiang, A. Sivachenko, 2012 .

Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.

Roman K. Thomas, J. Wolf, R. Buettner, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Juliann Chmielecki with Evolutionary Cancer Modeling Small Cell Lung Cancer − Optimization of Dosing for EGFR-Mutant Non

N. Socci, A. Viale, M. Ladanyi, 2011 .

Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.

R. Boellaard, M. Hellmich, Roman K. Thomas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overcoming drug resistance in ALK-rearranged lung cancer.

Roman K. Thomas, 2014, The New England journal of medicine.

Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer

K. Shokat, Roman K. Thomas, M. Peifer, 2017 .

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors

K. Shokat, Roman K. Thomas, M. Peifer, 2017, Science Translational Medicine.

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens

M. Tiemann, Roman K. Thomas, C. Gloeckner, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

H. Ji, Roman K. Thomas, W. Pao, 2016, Clinical Cancer Research.

K‐ras Mutation Subtypes in NSCLC and Associated Co‐occuring Mutations in Other Oncogenic Pathways

M. Hellmich, Roman K. Thomas, Y. Ko, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.

Roman K. Thomas, M. Sos, Anu Gupta, 2013, Journal of medicinal chemistry.

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.

Jochen Heil, Franziska Hoffgaard, Julian Engel, 2015, Journal of medicinal chemistry.

A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing.

Jeffrey C. Lee, Xiaojun Zhao, Roman K. Thomas, 2006, Cancer letters.

Systematically linking drug susceptibility to cancer genome aberrations

Roman K. Thomas, M. Sos, 2009, Cell cycle.

Personalized Therapy of Lung Cancer

Roman K. Thomas, J. Wolf, 2012, Oncology Research and Treatment.

Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

Roman K. Thomas, Paul D. Smith, E. Kilgour, 2012, Clinical Cancer Research.

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer

Roman K. Thomas, D. Planchard, M. Peifer, 2021, npj Precision Oncology.

AATF/Che‐1 acts as a phosphorylation‐dependent molecular modulator to repress p53‐driven apoptosis

Drew M. Lowery, M. Yaffe, Roman K. Thomas, 2012, The EMBO journal.

PD-L1 expression in small cell neuroendocrine carcinomas.

Roman K. Thomas, T. Zander, J. Wolf, 2015, European journal of cancer.

Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus

R. Boellaard, G. Giaccone, Roman K. Thomas, 2009, Journal of Nuclear Medicine.

Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors

Roman K. Thomas, M. Hallek, K. Kreuzer, 2013, Science Translational Medicine.

Arina Riabinska-Defective Tumors ATM in PRKDC Therapeutic Targeting of a Robust Non-Oncogene Addiction to

Roman K. Thomas, M. Hallek, K. Kreuzer, 2013 .

From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential.

V. Diehl, Roman K. Thomas, D. Ré, 2005, Blood.

Integrative analysis of multi‐omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer

H. Ji, Roman K. Thomas, Luonan Chen, 2021, Clinical and translational medicine.

Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death

Roman K. Thomas, O. Schilling, R. Schüle, 2020, Cancer Cell International.

LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells

Roman K. Thomas, M. Odenthal, J. Wolf, 2017, Scientific Reports.

therapeutic potential From Hodgkin's disease to Hodgkin lymphoma: biological insights and

V. Diehl, Roman K. Thomas, D. Ré, 2013 .

From Hodgkin's Disease to Hodgkin Lymphoma: Biological Insights and Therapeutic Potential

V. Diehl, Roman K. Thomas, D. Ré, 2005 .

Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment

H. Ji, Roman K. Thomas, Kwok-Kin Wong, 2023, National science review.

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

Roman K. Thomas, F. Leenders, J. Wolf, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An Activated ErbB 3 / NRG 1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells

W. Hahn, M. Meyerson, H. Greulich, 2022 .

Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

Roman K. Thomas, I. Melero, M. Larrayoz, 2021, Disease Models & Mechanisms.

Inhibition of Nuclear Translocation of Nuclear Factor-κB Despite Lack of Functional IκBα Protein Overcomes Multiple Defects in Apoptosis Signaling in Human B-Cell Malignancies

Roman K. Thomas, T. Zander, J. Wolf, 2005, Clinical Cancer Research.

Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells.

V. Diehl, Roman K. Thomas, D. Ré, 2004, The Lancet. Oncology.

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer

Roman K. Thomas, V. Walter, R. Büttner, 2017, Scientific Reports.

Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET)

Roman K. Thomas, T. Zander, G. Shapiro, 2008, PloS one.

A crucial requirement for Hedgehog signaling in small cell lung cancer

Roman K. Thomas, J. Sage, T. Stearns, 2011, Nature Medicine.

Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer

S. Gabriel, S. Nelson, M. Meyerson, 2007 .

Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

Roman K. Thomas, A. Melnick, M. Peifer, 2022, Blood cancer discovery.

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

A. Trumpp, A. Bradley, R. Rad, 2015, Cell.

Problems and promises of targeted therapy for Hodgkin's lymphoma

V. Diehl, Roman K. Thomas, T. Zander, 2005, Nature Clinical Practice Oncology.

Mutational analysis of the IκBα gene in activated B cell‐like diffuse large B‐cell lymphoma

V. Diehl, Roman K. Thomas, R. Küppers, 2004, British journal of haematology.

Genetic insight and therapeutic targets in squamous-cell lung cancer

Roman K. Thomas, M. Sos, R. Thomas, 2012, Oncogene.

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

I. Jonassen, G. Getz, M. Meyerson, 2009, Proceedings of the National Academy of Sciences.

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272

M. Meyerson, B. Weir, A. Lowell, 2007, Oncogene.

A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine.

Roman K. Thomas, J. Heuckmann, R. Thomas, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.

M. Meyerson, D. Tenen, H. Greulich, 2008, Cancer Research.

Comprehensive genomic characterization of squamous cell lung cancers

Joshua M. Stuart, Brian D. O’Connor, Charles J. Vaske, 2012, Nature.

Somatic mutations affect key pathways in lung adenocarcinoma

Brian H. Dunford-Shore, T. Fennell, K. Cibulskis, 2008, Nature.

Characterizing the cancer genome in lung adenocarcinoma

Derek Y. Chiang, S. Gabriel, E. Lander, 2007, Nature.

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Roman K. Thomas, T. Zander, D. Seidel, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

I. Petersen, R. Beroukhim, H. Groen, 2010, Science Translational Medicine.

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Roman K. Thomas, M. Mino‐Kenudson, D. Haber, 2018, Cancer discovery.

Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer

Roman K. Thomas, M. Peifer, J. Wolf, 2017, Clinical Cancer Research.

A crucial requirement for Hedgehog signaling in small cell lung cancer

Roman K. Thomas, J. Sage, T. Stearns, 2011, Nature Medicine.

Pharmacodynamics of RAD001 measured by early FDG PET in patients with recurrent NSCLC

G. Giaccone, Roman K. Thomas, T. Zander, 2008 .

Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor Pathway

Roman K. Thomas, T. Zander, J. Wolf, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract 122: Comparative analysis of small cell lung cancer and other pulmonary neuroendocrine tumors

Roman K. Thomas, N. Hayes, L. Fernandez-Cuesta, 2016 .

BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer

Roman K. Thomas, J. Panse, T. Overbeck, 2018 .

Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer

J. Minna, Roman K. Thomas, L. Girard, 2023, The Journal of clinical investigation.

LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells

Roman K. Thomas, M. Odenthal, J. Wolf, 2017, Scientific Reports.

CGARS: cancer genome analysis by rank sums

Xin Lu, Roman K. Thomas, Martin Peifer, 2014, Bioinform..